Dermata Therapeutics, Inc. DRMA 深 滬
已收盤 01-09 16:00:00 美东时间
2.08
-0.060
-2.80%
華盛通- 最 高2.1899
- 今 開2.18
- 成交量 6.05万股
- 最 低 2.05
- 昨 收 2.14
- 總市值 213.51万
- 52周最高 23.70
- 市盈率 靜 --
- 換手率 5.90%
- 52周最低 1.58
- 委 比 48.78%
- 總股本 102.65万
- 歷史最高 16680.00
- 量 比 0.27
- 振 幅 6.54%
- 歷史最低 2.05
- 每 手 1
- 風險率 3.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Shares of Fonar Corp (NASDAQ:FONR) rose sharply in pre-market after the company...
2025-12-30 17:43
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.
2025-12-30 13:54
Why Is Dermata Therapeutics Stock Surging Wednesday?
Dermata Therapeutics rose after announcing a private placement offering of common shares, Series C warrants, and Series D warrants.
2025-12-25 00:32
Dermata Therapeutics shares are trading higher. The company announced a $12.4 million private placement.
Dermata Therapeutics shares are trading higher. The company announced a $12.4 m...
2025-12-24 21:57
Dermata Therapeutics Announces Private Placement Up To $12.4M
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and
2025-12-24 21:01
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wedn...
2025-11-20 05:07
Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.59) by 3.77 percent. This is a 91.92 percent increase over losses of $(20.41) per share
2025-11-15 05:07
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC)
2025-10-02 20:02
Dermata Therapeutics Presents Promising Phase 3 Trial Results
Dermata Therapeutics ( ($DRMA) ) has provided an update. On September 17, 2025,...
2025-09-17 18:29
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and
2025-09-10 20:09
